Egan-Jones Recommends Against Electing Dissident’s Full Slate of Nominees to Ziopharm Board - biospace.com -BoardProspects

Egan-Jones Recommends Against Electing Dissident’s Full Slate of Nominees to Ziopharm Board

biospace.com Dec 11 2020 BoardNews

Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today commented on an opinion issued by Egan-Jones Proxy Services (“Egan-Jones”) in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- Why Should We Care About Corporate Interlocks? also categorized in BoardNews
- Germany's Corporate Governance Problem also categorized in BoardNews
- Immune Pharma Names Dr. Jeff Paley To Its Board Of Directors also published in biospace.com
- Corporate Boards: Shifting From Aging Men To New Generation Of Women? also categorized in BoardNews
- Looking to Twitter to Reignite Tech I.P.O.'s also mentions Opinion
- Getting Gen-Y on Boards (of Directors) also categorized in BoardNews
- Six Years Later, The Problem at HP is Still the Board also categorized in BoardNews
- Have the Swiss Gone Cuckoo? also categorized in BoardNews
- 20 Taiwan Businesspeople To Watch -- James Kuo, Austin Liu and Andy Lu also categorized in BoardNews
- Blueprint Medicines (BPMC) Appoints Lynn Seely, MD to Board of Directors also published in biospace.com

Search:
Categories
1. BoardProspects Features:
  BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
Topics Mentioned
- Board
- Nasdaq
- Management
- Opinion
- Ziopharm Oncology
- Egan-Jones